Drug · CHEMBL641
ATOMOXETINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ATOMOXETINE. Drugs and targets, record CHEMBL641. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL641
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Atomoxetine component of ad-109, Atomoxetine component of ad-313, Atomoxetine component of ad109, Atomoxetine component of ad313
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | Norepinephrine transporter inhibitor | INHIBITOR | https://conductscience.org/library/genes/6530 |
Source ChEMBL
Diseases37
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| attention deficit-hyperactivity disorder | Approval | ATC and TTD | 88 | 86 | https://conductscience.org/library/drugs?q=MONDO_0007743 |
| obstructive sleep apnea syndrome | Phase 3 | ClinicalTrials.gov | 22 | 22 | https://conductscience.org/library/drugs?q=MONDO_0007147 |
| schizophrenia | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0005090 |
| Parkinson disease | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005180 |
| cocaine dependence | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005186 |
| Cognitive impairment | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0100543 |
| alcohol dependence | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0007079 |
| cannabis dependence | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005689 |
| Oppositional defiant disorder | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0010865 |
| autism spectrum disorder | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005258 |
1 to 10 of 37Source Open Targets
See all 37 diseasesTrials191
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00700427 | A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 3 | 2,017 | 2013-05-29 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT00190684 | Long-Term, Open Label Atomoxetine Study | Phase 3 | 1,553 | 2011-01-17 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT00190775 | A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | 502 | 2010-10-21 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT00510276 | Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes | Phase 4 | 445 | 2010-03-03 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT00447278 | A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents | Phase 3 | 399 | 2010-04-20 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT00962104 | Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder | Phase 3 | 391 | 2012-09-11 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT00320528 | Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 3 | 269 | 2010-01-06 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT00183391 | Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children | Phase 4 | 232 | 2018-06-06 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT00471354 | A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine | Phase 4 | 228 | 2009-12-31 | atomoxetine | Its name | ClinicalTrials.gov |
| NCT01133847 | Interventions for Children With Attention and Reading Disorders | Phase 4 | 222 | 2017-04-11 | atomoxetine | Its name | ClinicalTrials.gov |
1 to 10 of 191
See all 191 trialsComparisons in its trials55
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Atomoxetine vs Placebo: serious adverse events | 4 of 266 | 3 of 234 | 500 | NCT00190775 | Trial comparisons |
| Atomoxetine vs Placebo: serious adverse events | 1 of 220 | 1 of 225 | 445 | NCT00510276 | Trial comparisons |
| Atomoxetine vs OEST: serious adverse events | 2 of 199 | 2 of 199 | 398 | NCT00447278 | Trial comparisons |
| Atomoxetine vs Placebo: serious adverse events | 1 of 193 | 2 of 195 | 388 | NCT00962104 | Trial comparisons |
| Atomoxetine/Atomoxetine vs Placebo/Atomoxetine: serious adverse events | 1 of 120 | 0 of 89 | 209 | NCT00607919 | Trial comparisons |
| Atomoxetine vs Placebo: serious adverse events | 0 of 100 | 1 of 51 | 151 | NCT00191945 | Trial comparisons |
| Atomoxetine vs Placebo: serious adverse events | 0 of 107 | 0 of 32 | 139 | NCT00192023 | Trial comparisons |
| Atomoxetine vs Placebo: serious adverse events | 0 of 63 | 0 of 62 | 125 | NCT00546910 | Trial comparisons |
| Atomoxetine vs Placebo: serious adverse events | 0 of 63 | 0 of 62 | 125 | NCT00844753 | Trial comparisons |
| ATMX Only vs ATMX and OROS MPH: serious adverse events | 0 of 72 | 0 of 50 | 122 | NCT00585910 | Trial comparisons |
1 to 10 of 55
See all 55 comparisons in its trialsPapers from its trials108
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials29
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Stroop Color-Word Test | 9 | 5 | ConductCognition |
| Continuous Performance Test | 8 | 3 | ConductCognition |
| Stop-Signal Task | 4 | 2 | ConductCognition |
| Digit Span Test | 3 | 1 | ConductCognition |
| Paired Associate Learning | 3 | 0 | ConductCognition |
| Card Sorting Test (Berg) | 2 | 1 | ConductCognition |
| Go/No-Go Task | 2 | 1 | ConductCognition |
| 2-Back Task | 2 | 2 | ConductCognition |
| Rapid Visual Information Processing | 2 | 1 | ConductCognition |
| Trail Making Test A | 2 | 1 | ConductCognition |
1 to 10 of 29
See all 29 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL641
GET https://conductscience.org/api/drugs/v1/CHEMBL641/diseases?page=2